The Food and Drug Administration intends to make a sole source award to University of Colorado Denver (UCD) to conduct a pediatric pulmonary hypertension actigraphy endpoint clinical study and to report all actigraphy measurement and relevant clinical examination data to help addressing FDA's needs for scientific evidence on much needed efficacy endpoint development for pediatric pulmonary hypertension drug development in accordance with FAR 6.302-1. Only one responsible source and no other supplies or services will satisfy agency requirements.

Bid Protests Not Available